drugset / Trial / NCT06048536

Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch

NCT06048536

Phase 2 Completed 168 enrolled Mylan Pharmaceuticals Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

A single-center, randomized, open-label, parallel-group, multi-arm, phase II clinical trial in healthy women aged 18 to 35 years who have a documented ovulatory cycle prior to randomization.

Timeline

Start
2023-12-22
Primary completion
2024-01-18
Completion
2024-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject norelgestromin Unknown 2.43 mg Other
Subject norelgestromin Unknown 3.64 mg Other
Subject norelgestromin Unknown 4.86 mg Other

Indications

No indication recorded.